Targets › DRD4
17 programs from 16 companies in 37 trials: 17 Phase 2, 14 Phase 3, 3 Phase 1, 3 Phase 4; Neurology, Psychiatry, Cardiovascular; next expected readout Nov 2026.
G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. In addition to dopamine, also activated by epinephrine and norepinephrine, and by numerous synthetic agonists and drugs. (UniProt, P21917)
Open in Phaseline: the race on DRD4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dennis M. McNamara, MD, MS | Bromocriptine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 4 | Peripartum Cardiomyopathy, Postpartum | Jun 2028 |
| Massachusetts General Hospital | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 4 | Adrenoleukodystrophy | – |
| Jimma University | Bromocriptine mesylate D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Dilated Cardiomyopathy | Nov 2026 |
| Daniel Lindqvist | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Bipolar Disorder (BD) | Dec 2029 |
| MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Apomorphine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Idiopathic Parkinson's Disease | – |
| I.R.C.C.S. Fondazione Santa Lucia | Rotigotine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Alzheimer Disease | – |
| University of California, San Diego | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Anxiety Disorders | Nov 2026 |
| University of Liege | Apomorphine Hydrochloride D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Disorder of Consciousness | Dec 2026 |
| M.D. Anderson Cancer Center | Chlorpromazine Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, DRD2, DRD3, DRD4 | Phase 2 | Delirium | Feb 2027 |
| M.D. Anderson Cancer Center | Haloperidol Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor inverse agonist | HTR2A, DRD2, DRD3, DRD4 | Phase 2 | Delirium; Advanced Malignant Neoplasm; Advanced Cancers | Feb 2027 |
| Boryung Pharmaceutical | Olanzapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy … | May 2027 |
| Clinical Academic Center (2CA-Braga) | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Obsessive-Compulsive Disorder | Aug 2028 |
| University Hospital, Rouen | rotigotine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Kidney Diseases | Jul 2030 |
| Stanford University | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Depression - Major Depressive Disorder | Aug 2030 |
| Md. Moktadirul Hoque Shuvo | Trifluoperazine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Functional Dyspepsia | – |
| Serina Therapeutics | SER-252 (PEOZ-apomorphine) Dopamine receptor agonist (D1-like and D2-like dopamine receptors) | DRD1, DRD2, DRD3, DRD4, DRD5 | Phase 1 | PARKINSON DISEASE (Disorder) | Jan 2027 |
| Capital Medical University | Chlorpromazine Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, DRD2, DRD3, DRD4 | Phase 1 | Acute Ischemic Stroke | – |
Delirium (3) Schizophrenia (2) Advanced Malignant Solid Neoplasm (2) Multiple Myeloma (2) PARKINSON DISEASE (Disorder) (1) Advanced Malignant Neoplasm (1) Advanced Cancers (1) Schizophrenia and Related Disorders (1) Chemotherapy Induced Nausea and Vomiting (1) Oncology Patients Receiving Chemotherapy (1) Electroacupuncture (1) Advanced Cancer (1)
small molecule (16), protein or peptide (1)
M.D. Anderson Cancer Center (2) Serina Therapeutics (1) Boryung Pharmaceutical (1) University of Liege (1) Md. Moktadirul Hoque Shuvo (1) Daniel Lindqvist (1) Stanford University (1) University Hospital, Rouen (1) University of California, San Diego (1) Jimma University (1) I.R.C.C.S. Fondazione Santa Lucia (1) MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (1) Massachusetts General Hospital (1) Clinical Academic Center (2CA-Braga) (1) Capital Medical University (1) Dennis M. McNamara, MD, MS (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.